Grant C R, Holder B S, Liberal R, Heneghan M A, Ma Y, Mieli-Vergani G, Vergani D, Longhi M S
Department of Liver Studies, Division of Transplantation Immunology and Mucosal Biology, MRC Centre for Transplantation, King's College London, Faculty of Life Sciences and Medicine, London, UK.
Department of Paediatrics, Imperial College, London.
Clin Exp Immunol. 2017 Jul;189(1):71-82. doi: 10.1111/cei.12956. Epub 2017 Mar 27.
Autoimmune hepatitis (AIH) is characterized by overwhelming effector immune responses associated with defective regulatory T cells (T ). Several lines of evidence indicate CD4 as the main effectors involved in autoimmune liver damage. Herein we investigate the in-vitro effects of prednisolone, 6-mercaptopurine, cyclosporin, tacrolimus, mycophenolic acid (MPA) and rapamycin, immunosuppressive drugs (ISDs) used in AIH treatment, on the expression of proinflammatory cytokines, co-inhibitory molecules and ability to proliferate of CD4 CD25 cells, isolated from the peripheral blood of treatment-naive patients with AIH. We note that in healthy subjects (HS) following polyclonal stimulation and in the absence of ISDs, the expression of interferon (IFN)-γ, interleukin (IL)-17 and tumour necrosis factor (TNF)-α by CD4 effectors peaks at 48 h and decreases at 96 h to reach baseline levels. In contrast, in AIH the expression of all these proinflammatory cytokines continue rising between 48 and 96 h. Levels of programmed cell death-1 (PD-1), T cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) and cytotoxic T lymphocyte antigen-4 (CTLA-4) increase over 96-h culture both in HS and AIH, although with faster kinetics in the latter. Exposure to ISDs contains IFN-γ and PD-1 expression in AIH, where control over CD4 CD25 cell proliferation is also noted upon exposure to MPA. Treatment with tacrolimus and cyclosporin render CD4 CD25 cells more susceptible to T control. Collectively, our data indicate that in treatment-naive patients with AIH, all ISDs restrain T helper type 1 (Th1) cells and modulate PD-1 expression. Furthermore, they suggest that tacrolimus and cyclosporin may ameliorate effector cell responsiveness to T .
自身免疫性肝炎(AIH)的特征是与调节性T细胞(T)缺陷相关的压倒性效应免疫反应。多项证据表明CD4是参与自身免疫性肝损伤的主要效应细胞。在此,我们研究了泼尼松龙、6-巯基嘌呤、环孢素、他克莫司、霉酚酸(MPA)和雷帕霉素等用于AIH治疗的免疫抑制药物(ISDs)对从未经治疗的AIH患者外周血中分离出的CD4 CD25细胞的促炎细胞因子表达、共抑制分子表达及增殖能力的体外影响。我们注意到,在健康受试者(HS)中,多克隆刺激后且无ISDs时,CD4效应细胞产生的干扰素(IFN)-γ、白细胞介素(IL)-17和肿瘤坏死因子(TNF)-α在48小时达到峰值,96小时时下降至基线水平。相比之下,在AIH中,所有这些促炎细胞因子在48至96小时之间持续上升。在HS和AIH中,程序性细胞死亡蛋白-1(PD-1)、含T细胞免疫球蛋白和粘蛋白结构域分子-3(TIM-3)以及细胞毒性T淋巴细胞抗原-4(CTLA-4)的水平在96小时培养过程中均升高,尽管在AIH中变化更快。在AIH中,暴露于ISDs可抑制IFN-γ和PD-1表达,暴露于MPA时也可观察到对CD4 CD25细胞增殖的控制。用他克莫司和环孢素治疗使CD4 CD25细胞对T控制更敏感。总体而言,我们的数据表明,在未经治疗的AIH患者中,所有ISDs均抑制1型辅助性T细胞(Th1)并调节PD-1表达。此外,它们提示他克莫司和环孢素可能改善效应细胞对T的反应性。